Physics Should Get Its Act Together

George Keyworth, the Washington businessman who once served as science adviser to the President, was fond of calling on the scientific community to "get its act together" and start setting priorities. The words have the sound of reason. Surely not all science is equally important and, if scientists don't set the priorities, someone else will. But, of course, as Keyworth must have realized, it's not that simple. It was, for example, possible for nuclear physicists to reach a consensus of sorts th

Written byRobert Park
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

But, of course, as Keyworth must have realized, it's not that simple. It was, for example, possible for nuclear physicists to reach a consensus of sorts that the Continuous Electron Beam Accelerator Facility (CEBAF) is what they most need to re-invigorate their field. Money would not have been budgeted to build CEBAF without that consensus. Somewhere else, however, the decision had to be made that nuclear physics is worth revitalizing.

Who decides it is more important to build CEBAF than a cold neutron source for solid-state physics? Who decides that any project in physics is more important than mapping the human genome? And who decides how much to give science when there are pressing social needs that go unmet? Ultimately, our elected representatives must make those decisions. Our responsibility is to inform the politicians of what our science can do—but they won't hear us if we speak with too many ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies